Evidence for a role of opioids in epoxyeicosatrienoic acid-induced cardioprotection in rat hearts.
We previously demonstrated that several epoxyeicosatrienoic acids (EETs) produce reductions in myocardial infarct size in rats and dogs. Since a recent study demonstrated the release of opioids in mediating the antinociceptive effect of 14,15-EET, we hypothesized that endogenous opioids may also be involved in mediating the cardioprotective effect of the EETs. To test this hypothesis, we used an in vivo rat model of infarction and a rat Langendorff model. In the infarct model, hearts were subjected to 30 min occlusion of the left coronary artery and 2 h reperfusion. Animals were treated with 11,12-EET or 14,15-EET (2.5 mg/kg) alone 15 min before occlusion or with opioid antagonists [naloxone, naltrindole, nor-binaltorphimine (nor-BNI), and d-Phe-Cys-Tyr-d-Trp-Om-Thr-Pen-Thr-NH(2) (CTOP), a nonselective, a selective delta, a selective kappa, and a selective mu receptor antagonist, respectively] 10 min before EET administration. In four separate groups, antiserum to Met- and Leu-enkephalin and dynorphin-A-(1-17) was administered 50 min before the 11,12-EET administration. Infarct size expressed as a percent of the area at risk (IS/AAR) was 63.5 + or - 1.2, 45.3 + or - 1.0, and 40.9 + or - 1.2% for control, 11,12-EET, and 14,15-EET, respectively. The protective effects of 11,12-EET were abolished by pretreatment with either naloxone (60.5 + or - 1.8%), naltrindole (60.8 + or - 1.0%), nor-BNI (62.3 + or - 2.8%), or Met-enkephalin antiserum (63.2 + or - 1.7%) but not CTOP (42.0 + or - 3.0%). In isolated heart experiments, 11,12-EET was administered to the perfusate 15 min before 20 min global ischemia followed by 45 min reperfusion in control hearts or in those pretreated with pertussis toxin (48 h). 11,12-EET increased the recovery of left ventricular developed pressure from 33 + or - 1 to 45 + or - 6% (P < 0.05) and reduced IS/AAR from 37 + or - 4 to 20 + or - 3% (P < 0.05). Both pertussis toxin and naloxone abolished these beneficial effects of 11,12-EET. Taken together, these results suggest that the major cardioprotective effects of the EETs depend on activation of a G(i/o) protein-coupled delta- and/or kappa-opioid receptor.
Gross
Garrett J
GJ
Dept. of Pharmacology and Toxicology, Medical College of Wisconsin, 8701 Watertown Plank Rd., Milwaukee, WI 53226, USA. ggross@mcw.edu
Baker
John E
JE
Hsu
Anna
A
Wu
Hsiang-en
HE
Falck
John R
JR
Nithipatikom
Kasem
K
D015126:8,11,14-Eicosatrienoic Acid / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000701:Analgesics, Opioid / Q000037:antagonists & inhibitors; D000818:Animals; D004195:Disease Models, Animal; D019206:GTP-Binding Protein alpha Subunits, Gi-Go / Q000502:physiology; D008297:Male; D009203:Myocardial Infarction / Q000503:physiopathology / Q000517:prevention & control*; D015428:Myocardial Reperfusion Injury / Q000503:physiopathology / Q000517:prevention & control*; D009270:Naloxone / Q000494:pharmacology; D009271:Naltrexone / Q000031:analogs & derivatives / Q000494:pharmacology; D009292:Narcotic Antagonists / Q000494:pharmacology; D051381:Rats; D017207:Rats, Sprague-Dawley; D011957:Receptors, Opioid / Q000502:physiology; D013004:Somatostatin / Q000031:analogs & derivatives / Q000494:pharmacology
D000701:Analgesics, Opioid; D009292:Narcotic Antagonists; D011957:Receptors, Opioid; C049352:phenylalanyl-cyclo(cysteinyltyrosyl-tryptophyl-ornithyl-threonyl-penicillamine)threoninamide; D009270:Naloxone; C051844:norbinaltorphimine; D013004:Somatostatin; C046783:11,12-epoxy-5,8,14-eicosatrienoic acid; D009271:Naltrexone; C046782:14,15-epoxy-5,8,11-eicosatrienoic acid; D019206:GTP-Binding Protein alpha Subunits, Gi-Go; D015126:8,11,14-Eicosatrienoic Acid; C055382:naltrindole
Am J Physiol. 1997 Feb;272(2 Pt 1):C560-4
9124299
Am J Physiol Cell Physiol. 2007 Mar;292(3):C996-1012
16987999
Am J Physiol Heart Circ Physiol. 2008 Jun;294(6):H2838-44
18441205
J Pharmacol Exp Ther. 2008 Mar;324(3):1019-27
18171909
Am J Physiol Heart Circ Physiol. 2007 Sep;293(3):H1604-8
17545478
Am J Physiol Heart Circ Physiol. 2006 Aug;291(2):H537-42
16473964
Am J Physiol Heart Circ Physiol. 2003 Dec;285(6):H2463-70
12869377
Am J Physiol Heart Circ Physiol. 2003 Sep;285(3):H1032-9
12730057
Am J Physiol Heart Circ Physiol. 2000 Oct;279(4):H1989-98
11009489
J Mol Cell Cardiol. 2007 Mar;42(3):687-91
17217955
Prostaglandins Other Lipid Mediat. 2007 Jan;82(1-4):50-9
17164132
Am J Physiol. 1998 Aug;275(2):H378-84
9683423
J Mol Cell Cardiol. 2009 Jun;46(6):978-88
19336274
Circ Res. 2004 Sep 3;95(5):506-14
15256482
Cardiovasc Res. 2004 Aug 15;63(3):414-22
15276466
Circ Res. 2006 Aug 18;99(4):442-50
16857962
J Physiol. 2006 Sep 1;575(Pt 2):627-44
16793897
Life Sci. 2003 Oct 3;73(20):2591-602
12967683
Am J Physiol Heart Circ Physiol. 2005 Oct;289(4):H1652-61
16162869
Am J Physiol Heart Circ Physiol. 2009 Jul;297(1):H47-52
19448143
J Pharmacol Exp Ther. 2009 Jan;328(1):231-9
18836067
Am J Physiol Heart Circ Physiol. 2008 Mar;294(3):H1444-51
18203844
Am J Physiol Heart Circ Physiol. 2008 Nov;295(5):H2128-34
18835921
Basic Res Cardiol. 2008 May;103(3):203-15
17999026
Am J Physiol Heart Circ Physiol. 2003 Jul;285(1):H81-9
12637353
J Pharmacol Exp Ther. 2008 Aug;326(2):614-22
18492947
J Mol Cell Cardiol. 2007 Oct;43(4):437-44
17765919
Am J Physiol Heart Circ Physiol. 2008 Feb;294(2):H724-35
18055514
Biochem Biophys Res Commun. 1996 Jan 26;218(3):877-81
8579608
Cardiovasc Res. 2009 Jul 15;83(2):362-70
19401302